Monoclonal Antibodies Provide Small Benefits in Alzheimer Disease
By Elana Gotkine HealthDay Reporter
FRIDAY, Jan. 26, 2024 -- Monoclonal antibodies targeting amyloid provide small benefits on cognitive and functional scales, which do not meet the minimal clinically important difference, according to a review published in the January/February issue of the Annals of Family Medicine.
Mark H. Ebell, M.D., from the University of Georgia in Athens, and colleagues conducted a meta-analysis to evaluate clinically meaningful benefits and harms of monoclonal antibodies targeting amyloid in patients with Alzheimer dementia. Nineteen publications with 23,202 total participants that examined eight anti-amyloid antibodies were identified.
The researchers identified small improvements over placebo in the Alzheimer's Disease Assessment Scale-Cog-11 to -14 score, Mini Mental State Examination score, and Clinical Dementia Rating-Sum of Boxes scale score, as well as the combined functional scores. None of the changes exceeded the minimal clinically important difference, including lecanemab, aducanumab, and donanemab. Significantly increased risks for amyloid-related imaging abnormalities (ARIA)-edema (relative risk [RR], 10.29), ARIA-hemorrhage (RR, 1.74), and symptomatic ARIA-edema (RR, 24.3) were identified as harms (number needed to harm: nine, 13, and 86, respectively).
"Our meta-analysis shows that monoclonal antibodies targeting amyloid do not provide a clinically meaningful benefit, are associated with significant harms, and come at a high cost," the authors write.
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2024 HealthDay. All rights reserved.
Posted January 2024
Read this next
Self-Administered Gerocognitive Exam Improves Detection of Cognitive Issues in Primary Care
TUESDAY, July 2, 2024 -- A self-administered gerocognitive examination (SAGE) is easily incorporated into primary care provider (PCP) visits, and its use significantly increases...
Emergence of Psychosis in Alzheimer Disease Linked to Elevations in p-tau181
MONDAY, July 1, 2024 -- For individuals with Alzheimer disease (AD), the emergence of psychosis is associated with elevations in levels of plasma tau phosphorylated at threonine...
Cognitive Impairment Delayed With Genetic Variant
THURSDAY, June 20, 2024 -- Cognitive impairment is delayed among persons who are heterozygous for the apolipoprotein E3 Christchurch variant (APOE3Ch), according to a study...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.